Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 24Squamous Cell Carcinoma of Head and Neck 18Melanoma 17Colorectal Neoplasms 16Urinary Bladder Neoplasms 11Breast Neoplasms 11Liver Neoplasms 10Biliary Tract Neoplasms 10Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Lung Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Carcinoma, Renal Cell 9Neoplasms 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Neoplasm Metastasis 5Mesothelioma, Malignant 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Mesothelioma 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3

Interventions

durvalumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2tremelimumab 1telisotuzumab vedotin 1selinexor 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 12-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrent Squamous Cell Lung Carcinoma × tremelimumab × Clear all
NCT03373760 2023-06-09

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

SWOG Cancer Research Network

Phase 2 Completed
67 enrolled 17 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡